Marvel Biosciences Corp. develops novel therapies for autism spectrum disorder and related neurological and neurodevelopmental disorders through its wholly owned subsidiary, Marvel Biotechnology Inc. The company's lead therapeutic candidate, MB-204, is described as a fluorinated derivative of Istradefylline and an adenosine A2A receptor blocker.
Company news commonly covers MB-204 development, pediatric-friendly oral liquid formulation work, intellectual-property protection for purine compounds, scientific and partnering activity in neuroscience, and broader clinical or regulatory disclosures. Updates also reference potential disease areas tied to A2A receptor biology, including autism, depression, Alzheimer's disease, Rett syndrome and Fragile X syndrome, as well as capital-structure matters relevant to the public company.
Marvel Biosciences (OTC: MBCOF) identified two pediatric-friendly liquid formulations of its lead compound MB-204, supported by an NRC IRAP grant. In mice, both formulations achieved 79% and 91% oral bioavailability, improving exposure versus the company’s prior formulation and strengthening formulation IP and clinical readiness.
The work targets easier dosing for children and supports accelerated regulatory engagement and a pathway toward a Phase I trial.
Marvel Biosciences (OTC:MBCOF) amended the conversion price for its proposed non-brokered private placement of unsecured convertible debentures to $0.17 per Common Share. The Offering remains up to $500,000 in principal and unchanged otherwise, and is subject to TSX Venture Exchange approval.
Marvel Biosciences (OTC: MBCOF) announced a non-brokered private placement of unsecured convertible debentures up to $500,000 to fund drug formulation, toxicology studies and working capital. The Debentures carry 12% annual interest, mature December 31, 2027, and convert at $0.12 per share, subject to TSX Venture Exchange approval.
Interest may be paid in cash or shares; the company can force conversion if the 10-day VWAP reaches $0.60 for 10 consecutive trading days. Securities will have a standard four-month-and-one-day hold period.
Marvel Biosciences (OTC: MBCOF) secured strategic and financial support from 5 Horizons Ventures for its upcoming Phase I trial of lead candidate MB-204. 5 Horizons will fund an amount equivalent to 15% of the Company’s CRO costs, providing non-dilutive capital while Marvel works with CRO partner Novotech.
The Phase I study is expected to begin in Q2 2026 and will assess safety, tolerability, and pharmacokinetics in healthy subjects. Marvel also cites newly granted patents in the US and Japan plus prior non-dilutive support from NRC IRAP and Alberta Innovates.
Marvel Biosciences (OTCQB:MBCOF) announced that the U.S. Patent Office issued U.S. Patent No. 12,570,656 B2 on March 18, 2026, covering composition of matter and methods of use for lead candidate MB-204.
This marks the third jurisdictional composition patent after Japan and China, strengthens MB-204's intellectual property, and follows completed pre-clinical toxicology and efficacy studies in depression and multiple autism models, with ongoing testing in Fragile X models.
Marvel Biosciences (OTCQB: MBCOF) is sponsoring the 3rd European Purine Meeting in Bordeaux, France, from June 30 to July 3, 2026 as a platinum-level sponsor.
The meeting gathers global purine researchers to share discoveries on purinergic signaling and its role in neurological disorders, including Alzheimer's disease and autism.
Marvel Biosciences (OTC: MBCOF) awarded 50,001 deferred share units (DSUs) to its three independent directors in lieu of cash directors' fees. The DSUs vest on February 17, 2027, are settled on a director's separation and expire 365 days after separation. The deemed value uses the VWAP $0.15 for February 17, 2026 multiplied by the number of DSUs.
Marvel Biosciences (OTCQB: MBCOF) is receiving advisory services and funding from the NRC IRAP to develop a pediatric-friendly, small-volume liquid formulation of lead compound MB-204 for neurodevelopmental disorders including autism, Rett syndrome, and Fragile X syndrome.
The program will evaluate multiple liquid approaches to identify a stable, reproducible format for oral syringe or feeding-tube delivery, support Canadian R&D partnerships, and generate data to inform future pediatric clinical trials and regulatory engagement.
Marvel Biosciences (OTCQB: MBCOF) announced that the Japan Patent Office granted Japanese Patent No. 2022-554855 for composition of matter and methods of use for MB-204, its lead therapeutic candidate. This is the second major jurisdiction to grant composition-of-matter protection for MB-204, strengthening global IP coverage.
MB-204 is a fluorinated analogue of istradefylline, has improved pharmacokinetics versus the parent compound, completed preclinical toxicology, and showed robust preclinical efficacy in depression and multiple autism models, including Rett syndrome; evaluations in Fragile X models are ongoing.
Marvel Biosciences (MBCOF) announced the award of 35,697 deferred share units (DSUs) to its three independent directors in lieu of cash directors' fees, with all DSUs vesting on October 31, 2026.
Vested DSUs will be settled when a director separates from service and expire 365 days after that separation. The DSUs' deemed value is calculated using the VWAP of $0.21 for the corporation's common shares on the TSX Venture Exchange on October 31, 2025 multiplied by the number of DSUs awarded.